IMPACT OF AMYLOID PET ON PATIENT MANAGEMENT: EARLY RESULTS FROM THE IDEAS STUDY

2017 ◽  
Vol 13 (7) ◽  
pp. P1474 ◽  
Author(s):  
Gil D. Rabinovici ◽  
Constantine Gatsonis ◽  
Charles Apgar ◽  
Ilana F. Gareen ◽  
Lucy Hanna ◽  
...  
2018 ◽  
Vol 46 (3-4) ◽  
pp. 154-167 ◽  
Author(s):  
Yejin Kim ◽  
Paul Rosenberg ◽  
Esther Oh

Background: Molecular imaging of brain amyloid for the diagnosis of Alzheimer’s disease (AD) using positron emission tomography (PET) has been approved for use in clinical practice by the Food and Drug Administration (FDA) since 2012. However, the clinical utility and diagnostic impact of amyloid PET imaging remain controversial. We conducted a review of the recent studies investigating clinical utility of amyloid PET imaging with focus on changes in diagnosis, diagnostic confidence, and patient management. Summary: A total of 16 studies were included in the final analysis. Overall rate of changes in diagnosis after amyloid PET ranged from 9 to 68% (pooled estimate of 31%, 95% CI 23–39%). All studies reported overall increase in diagnostic confidence or diagnostic certainty after amyloid PET. Changes in patient management ranged from 37 to 87%; the most common type of change in management reported was either the initiation or discontinuation of planned AD medications. Key Messages: Amyloid PET imaging led to moderate to significant changes in diagnosis, diagnostic confidence, and subsequent patient management. It may be most useful in patients with high level of diagnostic uncertainty even after the completing the standard workup.


2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Christopher Buckley ◽  
Juan Domingo Gispert ◽  
Daniele Altomare ◽  
Christian Moro ◽  
Santiago Bullich ◽  
...  

2020 ◽  
Vol 16 (S5) ◽  
Author(s):  
Léa Poitrine ◽  
Daniele Altomare ◽  
Christian Moro ◽  
Lyduine Collij ◽  
Isadora Lopes Alves ◽  
...  

2017 ◽  
Vol 13 (7) ◽  
pp. P1474-P1475
Author(s):  
Arno de Wilde ◽  
Wiesje Pelkmans ◽  
Femke H. Bouwman ◽  
Jurre Verwer ◽  
Colin Groot ◽  
...  

2017 ◽  
Vol 44 (3-4) ◽  
pp. 129-143 ◽  
Author(s):  
Michael J. Pontecorvo ◽  
Andrew Siderowf ◽  
Bruno Dubois ◽  
P. Murali Doraiswamy ◽  
Giovanni B. Frisoni ◽  
...  

Aims: To evaluate the impact of amyloid PET imaging on diagnosis and patient management in a multicenter, randomized, controlled study. Methods: Physicians identified patients seeking a diagnosis for mild cognitive impairment or dementia, possibly due to Alzheimer disease (AD), and recorded a working diagnosis and a management plan. The patients underwent florbetapir PET scanning and were randomized to either immediate or delayed (1-year) feedback regarding amyloid status. At the 3-month visit, the physician updated the diagnosis and recorded a summary of the actual patient management since the post-scan visit. The study examined the impact of immediate versus delayed feedback on patient diagnosis/management at 3 and 12 months. Results: A total of 618 subjects were randomized (1:1) to immediate or delayed feedback arms, and 602 subjects completed the 3-month primary endpoint visit. A higher proportion of patients in the immediate feedback arm showed a change in diagnosis compared to the controls (32.6 vs. 6.4%; p = 0.0001). Similarly, a higher proportion of patients receiving immediate feedback had a change in management plan (68 vs. 55.5%; p < 0.002), mainly driven by changes in AD medication. Specifically, acetylcholinesterase inhibitors were prescribed to 67% of the amyloid-positive and 27% of the amyloid-negative subjects in the information group compared with 56 and 43%, respectively, in the control group (p < 0.0001). These between-group differences persisted until the 12-month visit. Conclusion: Knowledge of the amyloid status affects the diagnosis and alters patient management.


2003 ◽  
Vol 8 (4) ◽  
pp. 4-5
Author(s):  
Christopher R. Brigham ◽  
James B. Talmage

Abstract Permanent impairment cannot be assessed until the patient is at maximum medical improvement (MMI), but the proper time to test following carpal tunnel release often is not clear. The AMA Guides to the Evaluation of Permanent Impairment (AMA Guides) states: “Factors affecting nerve recovery in compression lesions include nerve fiber pathology, level of injury, duration of injury, and status of end organs,” but age is not prognostic. The AMA Guides clarifies: “High axonotmesis lesions may take 1 to 2 years for maximum recovery, whereas even lesions at the wrist may take 6 to 9 months for maximal recovery of nerve function.” The authors review 3 studies that followed patients’ long-term recovery of hand function after open carpal tunnel release surgery and found that estimates of MMI ranged from 25 weeks to 24 months (for “significant improvement”) to 18 to 24 months. The authors suggest that if the early results of surgery suggest a patient's improvement in the activities of daily living (ADL) and an examination shows few or no symptoms, the result can be assessed early. If major symptoms and ADL problems persist, the examiner should wait at least 6 to 12 months, until symptoms appear to stop improving. A patient with carpal tunnel syndrome who declines a release can be rated for impairment, and, as appropriate, the physician may wish to make a written note of this in the medical evaluation report.


1988 ◽  
Vol 33 (9) ◽  
pp. 812-813
Author(s):  
C. R. Snyder
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document